GlassScriptPhysician profile
Sumaira Zareef
NPI 1982052791
$557.38
in general payments reported to CMS, 2019-2025
12 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $97.54 · 2024: $277 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $397.44 |
| Education | $159.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $124.41 | 2024 | Jakafi |
| Merck Sharp & Dohme LLC | $99.67 | 2024-2025 | Keytruda, Lynparza |
| Seagen INC. | $69.99 | 2023 | |
| Novocure INC. | $68.10 | 2025 | Optune Lua (Novottf-200t) |
| Sumitomo Pharma America, INC. | $37.99 | 2024-2025 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $34.85 | 2024-2025 | Ultomiris |
| Astellas Pharma US INC | $27.55 | 2023 | Cresemba |
| Lilly USA, LLC | $25.75 | 2024 | Verzenio |
| Legend Biotech USA INC. | $23.58 | 2025 | Carvykti |
| Exelixis INC. | $16.76 | 2024 | Cabometyx |
| Pfizer INC. | $14.42 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.31 | 2024 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumaira Zareef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.